Kyverna rings the Nasdaq opening bell on Feb. 8, 2024 (Lei Lei Wu for Endpoints News)

Kyver­na surges af­ter IPO, and CEO lays out plans for cell ther­a­py in im­mune dis­eases

Kyver­na Ther­a­peu­tics start­ed its first day as a pub­lic biotech on a strong note, with its shares $KYTX ris­ing more than 50% Thurs­day af­ter­noon af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.